1908444-28-9

Basic information

• Product Name: Obeticholic Acid impurity
• Synonyms: Obeticholic Acid impurity;(4R)-4-((3R,5R,7S,10R,13R,17R)-6-ethylidene-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid;Obeticholic acid IMP
• CAS NO: 1908444-28-9
• Molecular Formula: C52H86O7
• Molecular Weight: 823.24
• Mol File: 1908444-28-9.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Obeticholic Acid impurity(CAS DataBase Reference)
• NIST Chemistry Reference: Obeticholic Acid impurity(1908444-28-9)
• EPA Substance Registry System: Obeticholic Acid impurity(1908444-28-9)

Safety Data

• Hazardous Substances Data: 1908444-28-9(Hazardous Substances Data)

Usage

Uses

7-epi-Obeticholic Acid 3-Obeticholate Ester is a dimer of Obeticholic Acid (E899810). Obeticholic Acid is a derivative of the bile acid Chenodeoxycholic Acid (C291900). Obeticholic Acid is a potent activator of the farnesoid X nuclear receptor which reduces liver fat and fibrosis in animal models of fatty liver disease.

Relevant articles and documents

Preparation method of obeticholic acid impurities

The invention discloses a preparation method of obeticholic acid impurities, relates to a synthesis method of five impurities of obeticholic acid, and has important significance for synthesizing high-quality obeticholic acid. (E)-3 [beta]-hydroxy-6-ethylene-7-keto-5[ beta]-cholestane-24-acid (D), 3 [alpha], 7 [alpha]-dihydroxy-6 [beta]-ethyl-5 [beta]-cholestane-24-acid (F), 3 [alpha], 7 [beta]-dihydroxy-6 [beta]-ethyl-5 [beta]-cholestane-24-acid (G), 3 [alpha]-(3 [alpha], 7 [alpha]-dihydroxy-6 [alpha]-ethyl-5 [beta]-cholestane-24-acyloxy)-7 [alpha]-hydroxy-6 [alpha]-ethyl-5 [beta]-cholestane-24-acid (I) and 3-keto-7 [alpha]-hydroxy-6 [alpha]-ethyl-5 [beta]-cholestane-24-acid (L) are mainly researched.

A [...] dimer impurity and its preparation method (by machine translation)

The invention relates to a [...] dimer impurity and its preparation method, the preparation method comprises the following sequence of steps carried out: S1: [...] dimer impurity crude compound preparation; S2: [...] dimer impurity crude compound column chromatography separation and purification. The purpose of this invention is that the preparation [...] synthesis and degradation in the process of dimer impurity, can better control the quality of the [...], improve the drug safety. (by machine translation)